Stock NAMS FRAZIER LIFESCIENCES ACQUISITION CORPORATION
Add to a list
To use this feature you must be a member
Log inSign up

All News Frazier Lifesciences Acquisition Corporation

Equities

NAMS

NL00150012L7

End-of-day quote Nasdaq
Other stock markets
 06:00:00 2024-05-30 pm EDT 		5-day change 1st Jan Change
18.75 EUR +1.24% Intraday chart for Frazier Lifesciences Acquisition Corporation -0.37% +67.86%
May. 21 NewAmsterdam Pharma Company N.V. to Present New Clinical and Preclinical Data Highlighting Obicetrapib's Impact on Key RiskFactors for Cardiovascular Disease at Upcoming Medical Meetings CI
May. 16 Transcript : NewAmsterdam Pharma Company N.V. - Special Call

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in June
GL
NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in June
AQ
NewAmsterdam Pharma to Present New Clinical and Preclinical Data Highlighting Obicetrapib’s Impact on Key Risk Factors for Cardiovascular Disease at Upcoming Medical Meetings
GL
NewAmsterdam Pharma to Present New Clinical and Preclinical Data Highlighting Obicetrapib’s Impact on Key Risk Factors for Cardiovascular Disease at Upcoming Medical Meetings
AQ
NewAmsterdam Pharma Company N.V. to Present New Clinical and Preclinical Data Highlighting Obicetrapib's Impact on Key RiskFactors for Cardiovascular Disease at Upcoming Medical Meetings
CI
Transcript : NewAmsterdam Pharma Company N.V. - Special Call
TD Cowen Starts NewAmsterdam Pharma With Buy Rating
MT
Earnings Flash (NAMS) NEWAMSTERDAM PHARMA N.V. Reports Q1 Revenue $1.4M
MT
NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results
GL
NewAmsterdam Pharma Company N.V. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GL
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
NewAmsterdam Pharma to Host R&D Day with Key Opinion Leaders on May 16, 2024
GL
NewAmsterdam Pharma to Host R&D Day with Key Opinion Leaders on May 16, 2024
AQ
NewAmsterdam Pharma Enrolls Over 9,000 Patients in Pivotal Phase 3 PREVAIL Global Cardiovascular Outcome Trial Evaluating the Effect of Obicetrapib in Patients with Established Atherosclerotic Cardiovascular Disease
GL
NewAmsterdam Pharma Company N.V. Enrolls over 9,000 Patients in Pivotal Phase 3 Prevail Global Cardiovascular Outcome Trial Evaluating the Effect of Obicetrapib in Patients with Established Atherosclerotic Cardiovascular Disease
CI
NewAmsterdam Pharma Names Juliette Audet Chief Business Officer
MT
NewAmsterdam Pharma Announces the Appointment of Juliette Audet as Chief Business Officer
GL
NewAmsterdam Pharma Announces the Appointment of Juliette Audet as Chief Business Officer
AQ
Newamsterdam Pharma Announces the Appointment of Juliette Audet as Chief Business Officer
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. NAMS Stock
  4. News Frazier Lifesciences Acquisition Corporation